SCHEMBL1463271

SCHEMBL1463271

Clc1ccc2nc(NCC3CCNC3)oc2c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
S1PR3 Q99500 5/20 0.45
SOS1 Q07889 1/20 0.44
FBP1 P09467 1/20 0.42
MAOB P27338 2/20 0.41
HTR6 P50406 2/20 0.41
HCRTR1 O43613 2/20 0.41
HCRTR2 O43614 1/20 0.41
PIK3CG P48736 1/20 0.40
CTSL P07711 1/20 0.40
CTSS P25774 1/20 0.40
KDM1A O60341 1/20 0.40
MAPT P10636 1/20 0.40
RAB9A P51151 1/20 0.40
S1PR1 P21453 2/20 0.39
BRD4 O60885 1/20 0.39
ATAD2 Q6PL18 1/20 0.39
SSTR5 P35346 1/20 0.39
PSMB8 P28062 1/20 0.38
PSMB5 P28074 1/20 0.38
SYK P43405 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1462935 1.00 S1PR3 (0.45) S1PR3SOS1FBP1MAOBHTR6
Hydrochloric Acid SCHEMBL31267702 0.84 TDO2 (0.43) MAOBHTR6KDM1ABRD4ATAD2
SCHEMBL3657813 0.80 S1PR3 (0.47) S1PR3SOS1FBP1HCRTR1PIK3CG
SCHEMBL3657817 0.80 S1PR3 (0.47) S1PR3SOS1FBP1HCRTR1PIK3CG
SCHEMBL13543027 0.77 SSTR5 (0.50) S1PR3SOS1FBP1HTR6HCRTR1
Bromide SCHEMBL3573505 0.76 SSTR5 (0.49) S1PR3SOS1FBP1HTR6HCRTR1
SCHEMBL1463401 0.75 PIK3CA (0.45) MAOBHTR6HCRTR1HCRTR2KDM1A
SCHEMBL10370956 0.74 NPC1 (0.45) HTR6HCRTR1HCRTR2MAPTRAB9A
Hydrochloric Acid SCHEMBL31267688 0.73 TLR9 (0.49)
Hydrochloric Acid SCHEMBL31267713 0.73 REN (0.39) MAOBHTR6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8748430-B2 Pyrrolidin-3yl-methylamine quinoxaline derivatives Hoffmann-La Roche Inc (US) 2014-06-10 US disclosed
US-8748430-B2 Pyrrolidin-3yl-methylamine quinoxaline derivatives Hoffmann-La Roche Inc (US) 2014-06-10 US disclosed
US-20120232084-A1 PYRROLIDIN-3-YLMETHYL-AMINE AS OREXIN ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2012-09-13 US disclosed
US-20120232084-A1 PYRROLIDIN-3-YLMETHYL-AMINE AS OREXIN ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2012-09-13 US disclosed
US-8207220-B2 Substituted benzothiazoles as orexin antagonists HOFFMANN-LA ROCHE INC. (US) 2012-06-26 US disclosed
US-8207220-B2 Substituted benzothiazoles as orexin antagonists HOFFMANN-LA ROCHE INC. (US) 2012-06-26 US disclosed
EP-2303871-B1 PYRROLIDIN-3-YLMETHYL-AMINE AS OREXIN ANTAGONISTS HOFFMANN LA ROCHE (CH) 2012-05-09 EP disclosed
EP-2303871-B1 PYRROLIDIN-3-YLMETHYL-AMINE AS OREXIN ANTAGONISTS HOFFMANN LA ROCHE (CH) 2012-05-09 EP disclosed
US-7923470-B2 Benzooxazoles as orexin antagonists HOFFMANN-LA ROCHE INC. (US) 2011-04-12 US disclosed
US-7923470-B2 Benzooxazoles as orexin antagonists HOFFMANN-LA ROCHE INC. (US) 2011-04-12 US disclosed
US-7923470-B2 Benzooxazoles as orexin antagonists HOFFMANN-LA ROCHE INC. (US) 2011-04-12 US disclosed
EP-2303871-A1 PYRROLIDIN-3-YLMETHYL-AMINE AS OREXIN ANTAGONISTS F. Hoffmann-La Roche AG (CH) 2011-04-06 EP disclosed
US-20110071154-A1 PYRROLIDIN-3-YLMETHYL-AMINE AS OREXIN ANTAGONISTS KNUST HENNER 2011-03-24 US disclosed
US-20110071154-A1 PYRROLIDIN-3-YLMETHYL-AMINE AS OREXIN ANTAGONISTS KNUST HENNER 2011-03-24 US disclosed
WO-2010012620-A1 PYRROLIDIN-3-YLMETHYL-AMINE AS OREXIN ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2010-02-04 WO disclosed
WO-2010012620-A1 PYRROLIDIN-3-YLMETHYL-AMINE AS OREXIN ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2010-02-04 WO disclosed
US-20100029664-A1 PYRROLIDIN-3-YLMETHYL-AMINE AS OREXIN ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2010-02-04 US disclosed
US-20100029664-A1 PYRROLIDIN-3-YLMETHYL-AMINE AS OREXIN ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2010-02-04 US disclosed
US-20100029664-A1 PYRROLIDIN-3-YLMETHYL-AMINE AS OREXIN ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2010-02-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110071154-A1 PYRROLIDIN-3-YLMETHYL-AMINE AS OREXIN ANTAGONISTS HCRTR2, HCRTR1, NPY2R S1PR3 135/4885SOS1 1740/4885FBP1 4128/4885
US-20100029664-A1 PYRROLIDIN-3-YLMETHYL-AMINE AS OREXIN ANTAGONISTS HCRTR2, HCRTR1, NPY2R S1PR3 135/4885SOS1 1740/4885FBP1 4128/4885
US-20120232084-A1 PYRROLIDIN-3-YLMETHYL-AMINE AS OREXIN ANTAGONISTS HCRTR2, HCRTR1, NPY2R S1PR3 135/4885SOS1 1740/4885FBP1 4128/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.